Literature DB >> 29777702

microRNA-608 inhibits human hepatocellular carcinoma cell proliferation via targeting the BET family protein BRD4.

Ling He1, Dijuan Meng2, Shi-Hu Zhang3, Yi Zhang3, Zhengming Deng1, Lian-Bao Kong4.   

Abstract

Over-expression of the bromodomain and extraterminal (BET) family protein BRD4 is associated with hepatocellular carcinoma (HCC) progression. In the present study, we indentified a novel putative anti-BRD4 microRNA: microRNA-608 ("miR-608"). In HepG2 cells and primary human HCC cells, over-expression of miR-608, using a lentiviral construct, induced BRD4 downregulation and proliferation inhibition. Conversely, transfection of the miR-608 inhibitor increased BRD4 expression to promote HepG2 cell proliferation. Our results suggest that BRD4 is the primary target gene of miR-608 in HepG2 cells. shRNA-mediated knockdown or CRSIPR/Cas9-mediated knockout of BRD4 mimicked and overtook miR-608's actions in HepG2 cells. Furthermore, introduction of a 3'-untranslated region (3'-UTR) mutant BRD4 (UTR-A1718G) blocked miR-608-induced c-Myc downregulation and proliferation inhibition in HepG2 cells. In vivo, HepG2 xenograft tumor growth was significantly inhibited after expressing miR-608 or BRD4 CRSIPR/Cas9-KO construct. Importantly, BRD4 mRNA was upregulated in human HCC tissues, which was correlated with downregulation of miR-608. Together, we conclude that miR-608 inhibits HCC cell proliferation possibly via targeting BET family protein BRD4.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRD4; Cell growth; Hepatocellular carcinoma; c-Myc; microRNA-608

Mesh:

Substances:

Year:  2018        PMID: 29777702     DOI: 10.1016/j.bbrc.2018.05.108

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Toosendanin Suppresses Glioma Progression Property and Induces Apoptosis by Regulating miR-608/Notch Axis.

Authors:  Qiong Wang; Zeng Wang; Guilan Hou; Ping Huang
Journal:  Cancer Manag Res       Date:  2020-05-13       Impact factor: 3.989

2.  Therapeutic Targeting of BRD4 in Head Neck Squamous Cell Carcinoma.

Authors:  Yaping Wu; Yanling Wang; Pengfei Diao; Wei Zhang; Jin Li; Han Ge; Yue Song; Zhongwu Li; Dongmiao Wang; Laikui Liu; Hongbing Jiang; Jie Cheng
Journal:  Theranostics       Date:  2019-02-28       Impact factor: 11.556

3.  The circular RNA expression profile in ovarian serous cystadenocarcinoma reveals a complex circRNA-miRNA regulatory network.

Authors:  Minhui Zhuang; Jian Zhao; Jing Wu; Shilong Fu; Ping Han; Xiaofeng Song
Journal:  BMC Med Genomics       Date:  2021-12-02       Impact factor: 3.063

Review 4.  Biological Functions and Molecular Mechanisms of MiR-608 in Cancer.

Authors:  Juan Lu; Danhua Zhu; Lanjuan Li
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

Review 5.  Genomic Analyses of Non-Coding RNAs Overlapping Transposable Elements and Its Implication to Human Diseases.

Authors:  Eun Gyung Park; Hongseok Ha; Du Hyeong Lee; Woo Ryung Kim; Yun Ju Lee; Woo Hyeon Bae; Heui-Soo Kim
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

Review 6.  Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases.

Authors:  Jose Luis Morgado-Pascual; Sandra Rayego-Mateos; Lucia Tejedor; Beatriz Suarez-Alvarez; Marta Ruiz-Ortega
Journal:  Front Pharmacol       Date:  2019-11-08       Impact factor: 5.810

7.  Inhibitory effect of microRNA-608 on lung cancer cell proliferation, migration, and invasion by targeting BRD4 through the JAK2/STAT3 pathway.

Authors:  Weigang Xu; Dapeng Sun; Yanqin Wang; Xinlin Zheng; Yan Li; Yu Xia; Ya'nan Teng
Journal:  Bosn J Basic Med Sci       Date:  2020-08-03       Impact factor: 3.363

8.  BRD4/8/9 are prognostic biomarkers and associated with immune infiltrates in hepatocellular carcinoma.

Authors:  Yi-Ru Chen; Su-Shan Ouyang; Yan-Ling Chen; Ping Li; Hui-Wen Xu; Sen-Lin Zhu
Journal:  Aging (Albany NY)       Date:  2020-09-14       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.